Objective. We used the 28-joint Disease Activity Score (DAS28) and the European League Against Rheumatism Sjoren's Syndrome Disease Activity Index (ESSDAI) articular domain to assess the effect of rituximab (RTX) and abatacept (ABA) on articular involvement in primary Sjoren syndrome (pSS).
Methods. Patients with pSS treated with RTX (n = 18) or ABA ( n = 13) and having a DAS28 erythrocyte sedimentation rate (ESR)/C- reactive protein (CRP) level >= 3.2 at baseline were selected. Generalized estimating equations were used to analyze the DAS28 and ESSDAI articular domain over time.
Results. In the RTX group, DAS28-ESR/CRP decreased significantly up to 48 weeks. In the ABA group, DAS28-ESR/CRP decreased significantly up to 24 weeks. DAS28 correlated significantly with ESSDAI articular domain.
Conclusion. DAS28 is useful to evaluate the effect of biologicals on articular involvement in patients with pSS.
- PRIMARY SJÖGREN SYNDROME
- ARTICULAR INVOLVEMENT
- 28-JOINT DISEASE ACTIVITY SCORE
- ESSDAI ARTICULAR DOMAIN